Prescription Retinoids Compared: Tretinoin vs Adapalene vs Tazarotene vs Trifarotene

Topical prescription retinoids represent the most clinically proven drug class in dermatology for treating acne vulgaris, accelerating cellular turnover, and reversing ultraviolet-induced photoaging. However, patients and clinicians frequently face a confusing landscape of four distinct pharmacological generations: Tretinoin, Adapalene, Tazarotene, and the newest 4th-generation molecule, Trifarotene.

These four molecules are not interchangeable derivatives of vitamin A. They differ across five fundamental clinical parameters:

1. Receptor Selectivity: 1st-generation Tretinoin binds non-selectively to all three Retinoic Acid Receptors (RAR-α, RAR-β, RAR-γ). 3rd-generation Adapalene and Tazarotene selectively target RAR-β and RAR-γ. 4th-generation Trifarotene is a pure RAR-γ agonist with >20-fold selectivity over other subtypes, allowing potent epidermal gene transcription at an ultra-low 0.005% concentration.
2. FDA Photoaging vs Acne Approvals: Only two prescription topical retinoids hold formal US FDA New Drug Application (NDA) approvals for facial photoaging and fine wrinkles: Tretinoin (Renova 0.05% cream, NDA 019821, approved 1995) and Tazarotene (Avage 0.1% cream, NDA 021184, approved September 2002). Adapalene and Trifarotene hold FDA indications exclusively for acne vulgaris (their anti-aging utility is clinically established but off-label).
3. Benzoyl Peroxide (BPO) Stability: Unencapsulated tretinoin possesses an unstable polyene side chain that degrades and oxidizes by up to 50% within 2 hours of co-application with benzoyl peroxide in the presence of light. In contrast, the rigid aromatic naphthoic and terphenyl structures of Adapalene and Trifarotene are completely chemically stable with BPO.
4. Vehicle Formulation Advances: Modern micronized lotion delivery systems—such as Altreno (tretinoin 0.05% lotion, NDA 209844) and Arazlo (tazarotene 0.045% lotion, NDA 211882)—use polymeric emulsion meshworks and built-in humectants to dramatically cut trans-epidermal water loss (TEWL), erythema, and peeling compared to legacy generic creams and alcoholic gels.
5. Truncal Acne Efficacy: Trifarotene (Aklief, NDA 211527) is the only topical retinoid specifically studied and FDA-approved for large-surface truncal acne (chest, shoulders, back), enabled by rapid hepatic microsomal metabolism that prevents systemic drug accumulation.

The master comparison matrix below outlines the complete pharmacological and regulatory profile across all four generations.

---

The Four Generations of Prescription Retinoids: Receptor Selectivity Explained

To understand why different retinoids produce distinct clinical outcomes, one must examine their molecular interactions with human nuclear receptors. Retinoids exert their therapeutic effects by diffusing into epidermal keratinocyte nuclei and binding to Retinoic Acid Receptors (RARs).

Once activated, RARs heterodimerize with Retinoid X Receptors (RXRs), bind to specific DNA sequences called Retinoic Acid Response Elements (RAREs), and modulate the transcription of hundreds of genes controlling cell differentiation, epidermal proliferation, sebaceous lipid production, and collagenase inhibition.

RETINOIC ACID RECEPTOR (RAR) HIERARCHY & EPIDERMAL DISTRIBUTION

  HUMAN EPIDERMIS RECEPTOR COMPOSITION:
  ├── RAR-gamma (~90% of all epidermal RARs) ─── Primary driver of keratinocyte differentiation,
  │                                             desquamation, and comedolysis.
  ├── RAR-alpha (~10% of epidermal RARs) ────── Involved in myeloid differentiation & general signaling.
  └── RAR-beta (Minimal / inducible) ────────── Associated with cellular apoptosis & dermal remodeling.

  MOLECULAR BINDING PROFILES:
  ┌────────────────────────────────────────────────────────────────────────────────────────┐
  │ Tretinoin (1st Gen)    ───► Binds RAR-alpha (●) + RAR-beta (●) + RAR-gamma (●)        │
  │ Adapalene (3rd Gen)    ───► Binds RAR-beta (●)  + RAR-gamma (●)                       │
  │ Tazarotene (3rd Gen)   ───► Binds RAR-beta (●)  + RAR-gamma (●) [Highest Affinity]    │
  │ Trifarotene (4th Gen)  ───► Binds RAR-gamma (●●●●) [>20x Selectivity over Alpha/Beta] │
  └────────────────────────────────────────────────────────────────────────────────────────┘

Because RAR-γ constitutes approximately 90% of all retinoic acid receptors in the human epidermis, targeting RAR-γ drives primary comedolytic and textural benefits.

• Non-selective molecules like Tretinoin activate all three RAR subtypes, which provides broad biological coverage (critical for photoaging) but also engages systemic and non-target pathways that can amplify cutaneous irritation.
• 4th-generation Trifarotene's extreme selectivity for RAR-γ over RAR-α and RAR-β enables powerful comedolysis at a minute concentration of just 50 micrograms per gram (0.005%), whereas legacy tretinoin requires 500 to 1,000 micrograms per gram (0.05% to 0.1%).

---

Tretinoin (1st Gen): The Gold Standard for Photoaging and Wrinkles

Tretinoin (all-trans retinoic acid) was the first topical retinoid synthesized and approved by the FDA for acne in 1971 (NDA 016921, Retin-A). Over the subsequent five decades, it became the single most researched anti-aging molecule in dermatology.

TRETINOIN DERMAL REMODELING MECHANISM

  Topical Tretinoin Application
  ┌────────────────────────────────────────────────────────────────┐
  │ 1. Nuclear Binding to RAR-alpha, RAR-beta, and RAR-gamma      │
  └──────────────────────────────┬─────────────────────────────────┘
                                 │
         ┌───────────────────────┴───────────────────────┐
         ▼                                               ▼
  EPIDERMAL CELL TURNOVER                         DERMAL MATRIX PROTECTION
  ┌─────────────────────────────────────────┐   ┌─────────────────────────────────────────┐
  │ • Accelerates keratinocyte desquamation │   │ • Directly inhibits AP-1 transcription  │
  │ • Expels microcomedones & clears pores  │   │ • Blocks MMP-1 (collagenase) & MMP-8    │
  │ • Compresses stratum corneum basket-weave│   │ • Stimulates pro-collagen I & III       │
  │ • Disperses basal melanin clumps        │   │ • Increases dermal anchoring fibrils    │
  └─────────────────────────────────────────┘   └─────────────────────────────────────────┘

The Photoaging FDA Approval

In 1995, the FDA formally approved Renova (tretinoin 0.05% cream, NDA 019821) as an adjunctive therapeutic agent for the mitigation of fine facial wrinkles, mottled hyperpigmentation, and tactile roughness in patients who use comprehensive sun protection.

• Biochemical Action: Ultraviolet radiation activates the transcription factor AP-1 (activator protein-1), which upregulates Matrix Metalloproteinases (MMPs)—specifically MMP-1 (interstitial collagenase), MMP-3 (stromelysin), and MMP-9 (gelatinase)—that enzymatically fragment dermal type I and type III collagen. Tretinoin directly suppresses AP-1 activation, halting collagen degradation while simultaneously stimulating dermal fibroblasts to synthesize new anchoring fibrils and glycosaminoglycans.
• Concentration Options: Generic tretinoin is available in concentrations of 0.025%, 0.05%, and 0.1% in cream and gel bases. Clinical trials demonstrate that 0.05% provides the optimal balance between collagen synthesis and barrier tolerability; 0.1% increases peeling without delivering proportional long-term photoaging gains.

---

Adapalene (3rd Gen): Maximum Tolerability, OTC Access, and BPO Pairing

Approved for prescription acne treatment in 1996 (NDA 020380, Differin 0.1% gel) and switched to over-the-counter status in 2016, Adapalene is a synthetic naphthoic acid derivative engineered specifically to solve the chemical instability and barrier toxicity of 1st-generation retinoids.

ADAPALENE VS TRETINOIN MOLECULAR STABILITY

  TRETINOIN: Flexible Polyene Chain          ADAPALENE: Rigid Polycyclic Backbone
  ┌────────────────────────────────┐         ┌────────────────────────────────┐
  │  \  /  \  /  \  /  \  COOH     │         │   [ Adamantyl ] ── [ Naphthoic ]
  │   \/    \/    \/               │         │        \              /        │
  │ • Photolabile (degrades in UV) │         │ • 100% Photostable             │
  │ • Oxidized & destroyed by BPO  │         │ • Chemically stable with BPO   │
  └────────────────────────────────┘         └────────────────────────────────┘

Key Clinical Advantages of Adapalene

1. Superior Barrier Tolerability: Adapalene does not bind to cytosolic retinoic acid-binding proteins (CRABP-II) and selectively targets RAR-β and RAR-γ. In multi-center comparative clinical trials, adapalene 0.1% gel produced significantly lower scores for erythema, dryness, and scaling than tretinoin 0.025% and 0.05% creams during the initial 12 weeks of therapy.
2. Chemical Stability with Benzoyl Peroxide: Because of its rigid, polycyclic naphthoic acid core, adapalene does not undergo oxidative degradation when exposed to benzoyl peroxide. This enabled the development of fixed-dose combination formulations like Epiduo (adapalene 0.1% / BPO 2.5%) and Epiduo Forte (adapalene 0.3% / BPO 2.5%), which attack comedogenesis and Cutibacterium acnes proliferation simultaneously.
3. Off-Label Photoaging Efficacy: While adapalene is not FDA-approved for wrinkles, randomized double-blind clinical trials (e.g., Bagatin et al., Eur J Dermatol 2018) demonstrated that adapalene 0.3% gel achieved statistically equivalent reductions in periorbital and perioral fine wrinkling compared to tretinoin 0.05% cream over a 24-week period, with significantly fewer adverse local events.
4. OTC Accessibility: Differin 0.1% gel is available over-the-counter for approximately $15 to $25 per tube, making it the most accessible starting retinoid for acne and texture.

---

Tazarotene (3rd Gen): The Most Potent Receptor Binder for Acne and Photodamage

Tazarotene is an acetylenic synthetic retinoid prodrug. Upon topical application, cutaneous esterases rapidly cleave tazarotene into its active metabolite, tazarotenic acid, which binds to RAR-β and RAR-γ with an affinity up to 10-fold higher than tretinoin.

TAZAROTENE PRODRUG CONVERSION & DUAL FDA INDICATIONS

  Topical Tazarotene (Tazorac / Avage / Arazlo)
  ┌─────────────────────────────────────────────────────────────┐
  │ Cutaneous Esterase Cleavage in Skin                         │
  └──────────────────────────────┬──────────────────────────────┘
                                 │
                                 ▼
  Active Tazarotenic Acid (High-Affinity RAR-beta / RAR-gamma)
  ┌─────────────────────────────────────────────────────────────┐
  │ • Downregulates MRP-8 (inflammation marker)                 │
  │ • Suppresses Keratin 6, 16, and 17 (hyperproliferation)     │
  │ • Blocks cornified envelope formation & clears microcomedones│
  └──────────────────────────────┬──────────────────────────────┘
                                 │
         ┌───────────────────────┴───────────────────────┐
         ▼                                               ▼
  FDA ACNE APPROVAL                               FDA PHOTOAGING APPROVAL
  ┌─────────────────────────────────────────┐   ┌─────────────────────────────────────────┐
  │ Tazorac 0.05%/0.1% Gel/Cream (NDA 020600)│   │ Avage 0.1% Cream (NDA 021184, 2002)     │
  │ Arazlo 0.045% Lotion (NDA 211882, 2019)  │   │ • Indicated for facial fine wrinkling,  │
  │ • Most rapid comedolysis in clinical    │   │   mottled hyperpigmentation, and        │
  │   comparative trials                    │   │   tactile roughness                     │
  └─────────────────────────────────────────┘   └─────────────────────────────────────────┘

The Avage Photoaging Landmark

Competitor guides frequently assert that tretinoin is the only FDA-approved retinoid for wrinkles. This is factually incorrect. On September 30, 2002, the FDA approved Avage (tazarotene 0.1% cream, NDA 021184) for the mitigation of facial fine wrinkling, facial mottled hyperpigmentation, and benign facial lentigines in patients with comprehensive sun protection programs.

• Pivotal Trial Evidence (Kang et al., JAAD 2005): In a multicenter, randomized, double-blind vehicle-controlled trial (N=563), tazarotene 0.1% cream demonstrated statistically significant superiority over vehicle in reducing fine wrinkles, coarse wrinkles, mottled hyperpigmentation, and elastosis. Histological biopsies confirmed a significant increase in epidermal thickness and dermal collagen deposition.
• The Tolerability Tradeoff: Tazarotene's high receptor potency makes legacy generic 0.1% creams and gels notorious for causing intense retinization dermatitis (severe peeling and erythema). As detailed below, modern micronized lotion engineering has solved this hurdle.

---

Trifarotene (4th Gen): Targeted RAR-gamma Selectivity for Facial and Truncal Acne

Approved by the FDA in October 2019 (NDA 211527, Aklief 0.005% cream), Trifarotene is the first and only 4th-generation selective retinoid.

TRIFAROTENE (AKLIEF) PHARMACOKINETICS & TRUNCAL ACNE APPLICATION

  Application: Face (0.5g) + Chest/Shoulders/Back (1.5g)
  ┌─────────────────────────────────────────────────────────────┐
  │ 1. Direct Targeting of Epidermal RAR-gamma (>20x vs Alpha)  │
  │ • Potent comedolysis at ultra-low 0.005% (50 mcg/g) dose    │
  └──────────────────────────────┬──────────────────────────────┘
                                 │
                                 ▼
  Systemic Absorption into Bloodstream
  ┌─────────────────────────────────────────────────────────────┐
  │ 2. Rapid Hepatic Microsomal Metabolism via CYP2C9 & CYP3A4  │
  │ • Cleared in minutes; plasma half-life ~5 minutes in liver  │
  │ • Zero systemic drug accumulation across large body surfaces│
  └─────────────────────────────────────────────────────────────┘

The PERFECT 1 & PERFECT 2 Phase 3 Trials

In the pivotal Phase 3 randomized, double-blind trials published by Tan et al. (Journal of the American Academy of Dermatology, 2019, N=2,420):

• Facial Efficacy: Trifarotene achieved highly significant Investigator Global Assessment (IGA) success and lesion reduction compared to vehicle as early as Week 2.
• Truncal Efficacy: Trifarotene is the only retinoid evaluated and specifically approved for extensive truncal acne (chest, shoulders, and back).
• Systemic Safety: When applied across large body surface areas (up to 2.0 grams daily), trifarotene is rapidly metabolized by hepatic microsomal enzymes (CYP2C9 and CYP3A4), preventing systemic drug accumulation. Plasma levels remain below detectable thresholds in the vast majority of patients.

---

Vehicle Formulation Matters: Why Micronized Lotions (Altreno, Arazlo) Reduce Peeling

For decades, patient compliance with prescription retinoids was compromised by vehicle chemistry. Generic formulations suspended crystalline drug particles in heavy mineral creams (which can clog acneic pores) or volatile alcohol-based gels (which strip the lipid barrier).

In recent years, polymeric emulsion engineering has transformed retinoid delivery:

VEHICLE ARCHITECTURE: GENERIC CREAM VS POLYMERIC LOTION

   GENERIC RETINOID CREAM / GEL                MICRONIZED POLYMERIC LOTION
   (Uneven Drug Clumps + Alcohol Base)         (Altreno 0.05% / Arazlo 0.045%)
   ┌─────────────────────────────────────┐     ┌─────────────────────────────────────┐
   │ [ Drug Chunk ]    [ Bare Surface ]  │     │ ≋≋ Polymeric Honeycomb Mesh ≋≋≋     │
   │       │                             │     │   • Micronized micro-droplets       │
   │       ▼                             │     │   • Hyaluronic Acid + Collagen      │
   │ Acute localized barrier breakdown   │     │   • Controlled uniform release      │
   │ High TEWL, severe peeling, flaking  │     │   • Zero pore-clogging heavy waxes  │
   └─────────────────────────────────────┘     └─────────────────────────────────────┘

1. Altreno (Tretinoin 0.05% Lotion, NDA 209844)

Altreno (Ortho Dermatologics / Bausch Health) suspends micronized tretinoin particles within a continuous aqueous phase containing hyaluronic acid, soluble collagen, and glycerin.

• Clinical Impact: In Phase 3 clinical trials, Altreno demonstrated equivalent comedolytic and anti-acne efficacy to standard 0.05% and 0.1% tretinoin, with rates of severe peeling, dryness, and erythema below 4%. Over 85% of patients reported excellent tolerability.

2. Arazlo (Tazarotene 0.045% Lotion, NDA 211882)

Arazlo utilizes a patented PrismaGel polymeric honeycomb emulsion matrix that encapsulates micronized tazarotene.

• Clinical Impact (Tanghetti et al., JDD 2020): In head-to-head comparative studies against Tazorac 0.1% cream, Arazlo 0.045% lotion delivered statistically equivalent reductions in inflammatory and non-inflammatory acne lesions while cutting patient-reported burning, stinging, and peeling in half.

For patients with sensitive skin or compromised barriers, initiating therapy with a modern micronized lotion eliminates the high dropout rates historically associated with generic retinoids.

---

Combining Retinoids with Benzoyl Peroxide, AHAs, and Vitamin C

Improper active ingredient layering is the leading cause of retinoid failure and chemical burns.

ACTIVE INGREDIENT COMPATIBILITY MATRIX

  Co-Applied Active       Tretinoin (Generic)   Adapalene (Differin)  Tazarotene / Trifarotene
  ─────────────────────────────────────────────────────────────────────────────────────────────
  Benzoyl Peroxide (BPO)  INCOMPATIBLE          COMPATIBLE            SEPARATE APPLICATION
                          (BPO oxidizes 50% of  (Chemically stable;   (Apply BPO in AM,
                          tretinoin in 2 hr)    e.g., Epiduo)         Retinoid in PM)
  ─────────────────────────────────────────────────────────────────────────────────────────────
  AHA / BHA Acids         SEPARATE NIGHTS       SEPARATE NIGHTS       SEPARATE NIGHTS
  (Glycolic / Salicylic)  (Excessive TEWL)      (Risk of irritation)  (Severe barrier damage)
  ─────────────────────────────────────────────────────────────────────────────────────────────
  L-Ascorbic Acid (Vit C) SEPARATE APPLICATION  SEPARATE APPLICATION  SEPARATE APPLICATION
                          (Vit C in AM;         (Vit C in AM;         (Vit C in AM;
                          Tretinoin in PM)      Adapalene in PM)      Retinoid in PM)
  ─────────────────────────────────────────────────────────────────────────────────────────────
  Niacinamide / Ceramides HIGHLY SYNERGISTIC    HIGHLY SYNERGISTIC    HIGHLY SYNERGISTIC
                          (Buffers barrier)     (Buffers barrier)     (Buffers barrier)
  ─────────────────────────────────────────────────────────────────────────────────────────────

1. Benzoyl Peroxide Rules: Never mix generic tretinoin and BPO in the same evening routine; BPO rapidly oxidizes the tretinoin molecule. (The only exception is Twyneo, which utilizes core-shell silica micro-encapsulation to physically isolate tretinoin 0.1% from BPO 3%). Adapalene and Trifarotene are chemically stable with BPO.
2. Exfoliating Acids (AHAs/BHAs): Glycolic acid, lactic acid, and salicylic acid should not be layered directly under or over prescription retinoids. Alternate nights or reserve acids for morning use once the skin is fully retinized.
3. Routine Sequencing: Apply gentle cleanser → hydrating humectant/niacinamide → pea-sized amount of retinoid → ceramide-rich barrier moisturizer. For sensitive skin, utilize the "sandwich technique" (moisturizer → retinoid → moisturizer).

For detailed layering protocols, see how to layer skincare routines and damaged skin barrier repair.

---

Safety Boundaries: Retinization, Purging, and Pregnancy Warnings

The Retinization Period vs The Acne Purge

• Retinization Dermatitis: Occurs during Weeks 1 to 4 as epidermal receptors adapt. Manifests as erythema, flaking, tightness, and stinging upon moisturizer application. Managed by reducing frequency to 2–3 nights weekly and reinforcing the lipid barrier.
• The Retinoid Purge: As cell turnover accelerates, microcomedones trapped deep in follicular infundibula are pushed to the surface simultaneously. The purge lasts 4 to 6 weeks and consists of small whiteheads and inflammatory papules in areas where you normally break out. For biological timelines, see the retinoid purge guide.

Pregnancy Contraindications and Teratogenicity

PREGNANCY WARNING & CONTRAINDICATION STATUS

  Molecule        FDA Pregnancy Category       Clinical Directive
  ─────────────────────────────────────────────────────────────────────────────────────────────
  Tazarotene      CATEGORY X (Boxed Warning)   STRICTLY CONTRAINDICATED; mandatory negative
                  (Legacy Rating)              pregnancy test within 2 weeks of initiation
  ─────────────────────────────────────────────────────────────────────────────────────────────
  Tretinoin       Category C                   DISCONTINUE upon pregnancy planning / conception
  ─────────────────────────────────────────────────────────────────────────────────────────────
  Adapalene       Category C                   DISCONTINUE upon pregnancy planning / conception
  ─────────────────────────────────────────────────────────────────────────────────────────────
  Trifarotene     Category C                   DISCONTINUE upon pregnancy planning / conception
  ─────────────────────────────────────────────────────────────────────────────────────────────

All prescription topical retinoids should be discontinued during pregnancy and lactation.

• Tazarotene Strict Warning: Tazarotene carries an explicit boxed contraindication (legacy Category X rating) because animal reproduction studies demonstrated teratogenic effects (spina bifida, hydrocephalus, and skull deformities) when absorbed systemically. Females of childbearing potential must have a negative pregnancy test within 2 weeks prior to starting tazarotene and use reliable contraception.
• Safe Alternatives: For pregnant or nursing patients, plant-derived bakuchiol or azelaic acid (FDA Category B) provide safe comedolytic and brightening alternatives.

---

Cost and Access Guide: OTC vs Generic vs Patented Lotions

Prescription retinoid costs vary significantly based on patent status, vehicle formulation, and whether the drug is prescribed for acne (often covered by commercial insurance for patients under 25–35) or photoaging (strictly cash-pay).

---

Frequently asked questions

Is tazarotene stronger than tretinoin?

Yes. Tazarotene binds to Retinoic Acid Receptors (RAR-β and RAR-γ) with an affinity up to 10 times higher than tretinoin. In clinical trials, tazarotene achieves faster comedolysis and superior reduction of inflammatory acne lesions. However, in generic cream bases, it also carries a higher risk of irritation; modern lotion formulations (Arazlo 0.045%) maintain this potency while significantly improving skin tolerability.

Is adapalene as effective as tretinoin for wrinkles and anti-aging?

While only tretinoin (Renova) and tazarotene (Avage) hold formal FDA approvals for facial photoaging, clinical head-to-head trials demonstrate that adapalene 0.3% gel produces statistically equivalent reductions in fine wrinkles and hyperpigmentation compared to tretinoin 0.05% cream over 24 weeks, with significantly lower rates of redness and peeling.

Which prescription retinoid causes the least irritation?

Adapalene 0.1% (Differin) is clinically documented as the gentlest prescription-strength retinoid, making it the ideal starting point for sensitive skin. Among higher-potency molecules, micronized lotion formulations like Altreno (tretinoin 0.05% lotion) and Arazlo (tazarotene 0.045% lotion) cause significantly less peeling and barrier damage than legacy generic creams or gels.

Can I use tretinoin with benzoyl peroxide?

Not in the same application. Benzoyl peroxide chemically oxidizes and degrades unencapsulated tretinoin on contact. If you use both, apply benzoyl peroxide in the morning and tretinoin in the evening. In contrast, adapalene and trifarotene are chemically stable with BPO and can be applied simultaneously (such as in fixed-dose Epiduo).

Is tazarotene FDA-approved for wrinkles?

Yes. In September 2002, the FDA approved Avage (tazarotene 0.1% cream, NDA 021184) for the mitigation of facial fine wrinkling, mottled hyperpigmentation, and tactile roughness. It is one of only two topical retinoids holding an official FDA photoaging indication.

Why is trifarotene prescribed for back and chest acne?

Trifarotene (Aklief 0.005%, NDA 211527) is the only retinoid evaluated and FDA-approved specifically for large-surface truncal acne. When applied across large body surface areas (chest, shoulders, and back), it is rapidly cleared by liver enzymes (CYP2C9/CYP3A4), preventing systemic drug accumulation while delivering potent RAR-γ comedolysis to thick body skin.

---

Sources

1. FDA CDER NDA Database: NDA 019821 — Renova (Tretinoin 0.05% Cream) Photoaging Approval (Decision Date: 1995). Available at: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019821
2. FDA CDER NDA Database: NDA 021184 — Avage (Tazarotene 0.1% Cream) Facial Photoaging Approval (Decision Date: September 30, 2002). Available at: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021184
3. FDA CDER NDA Database: NDA 209844 — Altreno (Tretinoin 0.05% Lotion) Approval (Decision Date: 2018). Available at: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209844
4. FDA CDER NDA Database: NDA 211882 — Arazlo (Tazarotene 0.045% Lotion) Approval (Decision Date: December 2019). Available at: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211882
5. FDA CDER NDA Database: NDA 211527 — Aklief (Trifarotene 0.005% Cream) Approval for Facial and Truncal Acne (Decision Date: October 2019). Available at: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211527
6. FDA CDER NDA Database: NDA 020380 / NDA 021753 — Differin (Adapalene 0.1% and 0.3% Gel) Approval. Available at: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020380
7. Tan J, et al. Randomized Phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne. J Am Acad Dermatol. 2019;80(6):1691-1699. Available at: https://pubmed.ncbi.nlm.nih.gov/30802558/
8. Kang S, et al. A multicenter, randomized, double-blind trial of tazarotene 0.1% cream in the treatment of photodamage. J Am Acad Dermatol. 2005;52(2):268-274. Available at: https://pubmed.ncbi.nlm.nih.gov/15692472/
9. Tanghetti EA, et al. Tazarotene 0.045% Lotion for Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Results from Two Phase 3 Trials. J Drugs Dermatol. 2020;19(1):70-77. Available at: https://pubmed.ncbi.nlm.nih.gov/31985914/
10. Bagatin E, et al. Comparable efficacy of adapalene 0.3% gel and tretinoin 0.05% cream as treatment for cutaneous photoaging. Eur J Dermatol. 2018;28(3):343-350. Available at: https://pubmed.ncbi.nlm.nih.gov/30105991/
11. DailyMed NLM: FDA Drug Label Information Repository. Available at: https://dailymed.nlm.nih.gov/dailymed/